Get startedLog in
    Picture of Roche Holding AG logo

    ROP — Roche Holding AG News Story

    0.000.00%
    ch flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Brief: Roche Says Giredrestrant Combination Improved Progression-Free Survival In Phase III Study

    Picture of Roche Holding AG logoRoche Holding AG
    01/10/2026 06:09
    BRIEF-Roche Says Giredrestrant Combination Improved Progression-Free Survival In Phase III Study
    Oct 1 (Reuters) - ROCHE HOLDING AG ROPC.S:
    • ROCHE’S GIREDESTRANT COMBINATION SIGNIFICANTLY IMPROVED PROGRESSION-FREE SURVIVAL IN ER-POSITIVE ADVANCED BREAST CANCER IN PHASE III EVERA DATA PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE
    • FDA SETS PDUFA GOAL DATE FOR GIREDRESTRANT ON NOV 30 AND DEC 18, 2026
    • GIREDRESTRANT COMBINATION SHOWS MANAGEABLE ADVERSE EVENTS WITH NO UNEXPECTED SAFETY FINDINGS
    • GIREDRESTRANT PLUS EVEROLIMUS REDUCES RISK OF DISEASE PROGRESSION OR DEATH BY 44%-62%
    • MEDIAN PFS 8.8 MONTHS WITH GIREDRESTRANT PLUS EVEROLIMUS IN ITT POPULATION
    • OS DATA SHOW POSITIVE TREND IN ITT AND ESR1-MUTATED POPULATIONS
    Source text: ID:nGNE4c4n5g
    Further company coverage: ROPC.S

     (Gdansk Newsroom)
     ((gdansk.newsroom@thomsonreuters.com; +48 587785269;))

    Recent news on Roche Holding AG

    See all news